Glipizide

Both formulations are labeled as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. They do not treat diabetic ketoacidosis or replace insulin in type 1 diabetes. Pediatric safety and effectiveness are not established. Neither label establishes glipizide as a cardiovascular-risk-reduction therapy.

Titrate to glucose response and hypoglycemia risk; the two maximum doses are not interchangeable.

Swallow XL whole; do not cut, crush, dissolve or chew it. Its empty shell may appear in stool. The XL label allows switching from IR to the nearest equivalent total daily dose once daily, within the XL maximum and with monitoring; an IR dose above 20 mg is not automatically carried over. Transfers from long-acting sulfonylureas require monitoring for overlapping hypoglycemia. Any insulin-to-glipizide transition is supervised and not a self-directed taper.

Use conservative initial and maintenance doses with renal or hepatic impairment, frailty or malnutrition. XL specifically starts hypoglycemia-predisposed patients, including renal impairment, at 2.5 mg. The labels do not provide a universal eGFR-based titration or fixed renal maximum.

IR formally contraindicates hypersensitivity, type 1 diabetes and diabetic ketoacidosis with or without coma. XL’s formal section lists hypersensitivity to glipizide/ingredients and sulfonamide derivatives; its indications/patient information exclude type 1 diabetes and ketoacidosis. G6PD deficiency and severe GI narrowing are XL avoid-use warnings rather than the formal section 4 list.

The selected labels do not contain a boxed warning. The IR prominent special cardiovascular warning and XL section 5.3 warning concern historical sulfonylurea evidence; their wording must not be presented as a modern glipizide-specific risk estimate.

Hypoglycemia, dizziness, diarrhea, tremor and other gastrointestinal symptoms are reported. Persistent allergic skin reactions require stopping; cholestatic jaundice and blood dyscrasias have been reported. Excess dosing can cause recurrent severe hypoglycemia even after apparent recovery. A conscious patient able to swallow can take oral glucose under the established rescue plan; coma, seizure or impaired swallowing requires emergency help and clinician-administered glucagon/IV glucose. Labels call for at least 24–48 hours of close monitoring after severe overdose. Dialysis is unlikely to help.

Insulin/other diabetes drugs, salicylates/NSAIDs, sulfonamide antibiotics, quinolones, coumarins and several other agents can increase hypoglycemia. Steroids, thiazide/other diuretics, thyroid hormones, some antipsychotics, estrogens and sympathomimetics can weaken glucose control. Alcohol and beta blockers may change control in either direction; beta blockers and other sympatholytics can mask symptoms. Adjust only after clinical review and glucose monitoring, including after withdrawal of an interacting drug.

Oral miconazole has been associated with severe hypoglycemia; risk with other miconazole routes is not established by these labels. Fluconazole increases glipizide exposure; monitor closely and consider dose changes. Give glipizide at least four hours before colesevelam: the supporting study specifically evaluated ER absorption, and both selected labels give this separation instruction.

Both labels warn about neonatal hypoglycemia from sulfonylureas and the risks of poor maternal glucose control. The current IR label retains older pregnancy wording and directs discontinuation at least ONE MONTH before expected delivery if used; Glucotrol XL directs at least TWO WEEKS. Coordinate replacement therapy rather than leaving diabetes untreated. IR advises deciding whether to stop nursing or the drug because infant hypoglycemia is possible. XL reports undetectable milk in one limited study, which is not conclusive, and calls for balancing benefits/risks and infant hypoglycemia monitoring. Jitters, poor feeding, excessive sleepiness, blue color, apnea or seizures need prompt assessment.

Safety and effectiveness in children are not established; no pediatric regimen is supplied. Older adults may be more sensitive to hypoglycemia and recognize it poorly, so start conservatively and reassess meals, renal function and interacting medicines.

IR labeling notes slowed metabolism/excretion and prolonged hypoglycemia in renal/hepatic dysfunction. XL has no dedicated graded renal PK study; metabolites may circulate longer with renal impairment. Hepatic biotransformation and protein binding support cautious low-dose treatment and prolonged-event monitoring. No labeled numeric renal-stage algorithm is invented.

Sulfonylurea receptor binding in pancreatic beta cells closes ATP-sensitive potassium channels and promotes insulin release. Functioning beta cells are required. Meal-stimulated insulin secretion is enhanced; response may decline over time and needs reassessment.

Glipizide is highly protein bound and cleared mainly by hepatic biotransformation; less than 10% is excreted unchanged. XL concentrations begin rising after two to three hours, peak about six to twelve hours and persist across its 24-hour interval. The terminal elimination half-life is about two to five hours. XL’s osmotic tablet controls delivery; its intact empty shell is expected, while shortened GI transit can reduce exposure.

Follow blood glucose and HbA1c to select the lowest effective dose and detect loss of response. Monitor more closely during titration, medication changes, acute illness, reduced food intake or organ dysfunction. Review symptoms, driving safety and the need for alternative therapy; glucose lowering alone is not evidence of cardiovascular protection.

Explain the correct formulation’s meal timing, regular meals, activity and glucose checks. Avoid alcohol with XL under its patient instructions. Carry the agreed glucose rescue treatment; seek immediate help for severe or recurrent low glucose and do not give oral food/drink to an unconscious person. Tell the prescriber about pregnancy, breastfeeding, allergy, organ disease, G6PD deficiency and GI narrowing. Never share medication or change doses independently.

The selected PD-Rx repackaged Apotex IR product is a white/off-white round scored 10-mg tablet, “APO” on one side and “GLP” over the score and “10” on the other; the 30-tablet repackager bottle is NDC 43063-861-30. Source and repackager packaging differ. Glucotrol XL 5 mg is white round/biconvex, marked “GXL 5”; 100-tablet bottle NDC 0049-0174-02. Generic appearances vary.

Apotex IR supplies white/off-white round scored 5- and 10-mg tablets with “APO” and “GLP” over the score and strength. A 2.5-mg starting dose requires confirming the dispensed product’s appropriate splitting instructions with the pharmacist. Glucotrol XL supplies 2.5-mg blue and 5-/10-mg white tablets; none should be split.

Apotex IR: 20–25°C; dispense in a tight, light-resistant container. Glucotrol XL: 20–25°C, excursions 15–30°C; protect from moisture/humidity and keep in the original dry container. Follow the specific dispensed/repackaged container and keep medicines out of children’s reach.